Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 18.0 | 68 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 12.0 | 83 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 18.0 | 50 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 12.5 | 60 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 18.0 | 60 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 11.0 | 65 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 16.5 | 54 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 93.0 | 62 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 194.0 | 53 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 842.5 | 66 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 1381.0 | 51 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 118.0 | 50 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 410.5 | 50 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 318.0 | 53 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 561.0 | 65 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 37.0 | 75 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 45.5 | 50 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 26.0 | 72 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 38.0 | 71 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 34.0 | 68 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 37.0 | 70 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 27.5 | 64 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 42.0 | 71 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 1606.0 | 57 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | IP-10 | 3979.0 | 61 |